The D3 trial is excited to announce that it has successfully completed recruitment in the trial at an exceptional speed. D3 is looking to see if a new tablet, a combination of two anti-HIV medicines, dolutegravir (DTG) and lamivudine (3TC), is as good and effective in treating HIV in children and young people living with HIV in comparison to the current paediatric anti-HIV medicines available.
The trial recruited 370 children from South Africa,
A new trial opened in May, aiming to find out if children and young people living with HIV can take two anti-HIV medicines instead of three. The trial has already recruited 57 participants in Uganda and Thailand.
People living with HIV have to take medicines for life. Therefore, it is important to ensure that these medicines work well and continue to be safe to take for children and young people living with HIV.